Constitution of a Biobank for Studies Related to Organ Transplantation (Lyon Centaure Biocollection)
Biological Material Bank for Studies Related to Organ Transplantation
This study aims to constitute a collection of biological materials from in transplant patients and to provide biological materials from transplanted patients in order :
i) validate new theory on the cause of allograft loss, ii) develop innovative biomarker for rejection and other transplantation-related conditions (such as BK virus nephropathy, Post-transplant lymphoproliferative disorder ( PTLD) ...)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Olivier Thaunat, MD
- Phone Number: +33 04 72 11 69 28
- Email: olivier.thaunat@chu-lyon.fr
Study Contact Backup
- Name: Emmanuel Morelon, MD
- Phone Number: +33 04 72 11 01 70
- Email: emmanuel.morelon@chu-lyon.fr
Study Locations
-
-
Rhône
-
Lyon, Rhône, France, 69003
- Recruiting
- Hôpital Edouard Herriot
-
Contact:
- Olivier THAUNAT, MD
- Phone Number: +33 04.72.11.69.28
- Email: olivier.thaunat@chu-lyon.fr
-
Contact:
- DANIEL SPERANDO, CRA
- Phone Number: +33 04.72.11.69.28
- Email: daniel.sperando@chu-lyon.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or Female patient ≥18 years old
- Recipient of an organ transplant
- Written informed consent
Exclusion Criteria:
- Non-affiliation to a social security system.
- Subjects deprived of liberties
- Pregnant or breastfeeding woman
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the biological samples
Time Frame: At inclusion
|
The goal of this study is to provide biological materials from transplanted patients
|
At inclusion
|
|
Change Biological Samples
Time Frame: Month 1
|
The goal of this study is to provide biological materials from transplanted patients
|
Month 1
|
|
Change Biological Samples
Time Frame: Month 3
|
The goal of this study is to provide biological materials from transplanted patients
|
Month 3
|
|
Change Biological Samples
Time Frame: Month 6
|
The goal of this study is to provide biological materials from transplanted patients
|
Month 6
|
|
Change Biological Samples
Time Frame: Month 12
|
The goal of this study is to provide biological materials from transplanted patients
|
Month 12
|
|
Change Biological Samples
Time Frame: Month 60
|
The goal of this study is to provide biological materials from transplanted patients
|
Month 60
|
|
Change Biological Samples
Time Frame: Month 120
|
The goal of this study is to provide biological materials from transplanted patients
|
Month 120
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Olivier Thaunat, MD, Edouard Herriot Hospital - Transplantation department
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 69HCL20_0964
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.